Form 4: Sanara MedTech Director Robert DeSutter Granted Restricted Stock Under Incentive Plan

Sanara MedTech Inc. Director Robert Andrew DeSutter received a grant of 3,746 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Summary

• Robert Andrew DeSutter, a Director and 10% Owner of Sanara MedTech Inc. (SMTI), was granted 3,746 shares of common stock.
• The transaction date for this acquisition was May 22, 2025.
• The shares were granted at a price of $0 per share, indicating they are part of a compensation or incentive plan.
• Following this transaction, Mr. DeSutter beneficially owns a total of 23,201 shares of common stock.
• The restricted stock grant is pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• The shares are subject to vesting conditions, specifically vesting on the earlier of the 2026 annual shareholder meeting or May 22, 2026, provided Mr. DeSutter continues to provide services to the Company through that date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued commitment from a key director and aligns their interests with shareholders, which is generally viewed favorably. There are no negative financial implications beyond minor dilution.

Positives

• The grant of restricted stock aligns the interests of Director Robert Andrew DeSutter with those of the shareholders, as his compensation is tied to the company's long-term performance.
• The transaction is part of a pre-approved 2024 Omnibus Long-Term Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• The issuance of new shares for compensation, even if restricted, can result in minor dilution for existing shareholders.

Risks

• The vesting of the restricted stock is contingent upon the reporting person continuing to provide services to the Company through the specified vesting dates (earlier of 2026 annual shareholder meeting or May 22, 2026).

Future Outlook

The future outlook for the granted shares is tied to their vesting schedule, which is set for the earlier of the 2026 annual shareholder meeting or May 22, 2026, provided the director continues to provide services to the company.

Industry Context

The granting of restricted stock to directors is a common practice across various industries, particularly in the healthcare and technology sectors, as a means of long-term incentive compensation and to align the interests of leadership with shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock grants as a component of director compensation is a standard practice in corporate governance, aligning with common benchmarks for incentivizing long-term commitment and performance.
• Companies like Medtronic (MDT) or Stryker (SYK) also utilize equity-based compensation plans for their directors and executives, reflecting a broad industry trend to tie leadership's financial interests to the company's stock performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of new shares but benefit from increased alignment of the director's interests with the company's long-term performance.
• Director (Robert Andrew DeSutter): Receives long-term equity compensation, incentivizing continued service and contribution to the company's success.

Next Steps

• The restricted shares will vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, subject to continued service.

Key Dates

Keywords

Sanara MedTech, SMTI, Restricted Stock, Stock Grant, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Corporate Governance